Full Press Release Details
NATICK, Mass. , March 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) releases its schedule of product-related clinical research at the 61th Annual Scientific Session of the American College of Cardiology/i2 Summit , March 24-27 in Chicago .
"Two-year results from the PLATINUM Workhorse clinical trial will provide important follow-up data on our next-generation PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent," said Keith D. Dawkins , M.D., Global Chief Medical Officer for Boston Scientific. "Additional analysis from the PLATINUM and PERSEUS trials will provide further insight into the performance of our platinum chromium stent platform."
Schedule of Events (All times are CST, with events to be held at the McCormick Place Convention Center)
Saturday, March 24
Sunday, March 25
Monday, March 26
Boston Scientific will present its latest cardiology, rhythm and vascular products at booth #3063 in the Exhibit Hall.
In the U.S., the WATCHMAN device is an investigational device, limited by applicable law to investigational use and not available for sale. XIENCE V is a trademark of the Abbott Laboratories group of companies. The PROMUS Stent is a private-labeled XIENCE V Stent manufactured by Abbott and distributed by Boston Scientific.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com .
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACT: Eric Olson 336-293-4393 (office) Media Relations Boston Scientific Corporation [email protected]
Sean Findlen 617-520-7268 (office) Media Relations Weber Shandwick [email protected]
Sean Wirtjes 508-652-5305 (office) Investor Relations Boston Scientific Corporation [email protected]
SOURCE Boston Scientific Corporation